HAGEDORN RESEARCH TODAY

Hagedorn Research fosters the interaction between academic/biotechnological scientists and research groups to stimulate the translational ideas in early diabetes discovery research. Today, Hagedorn Research is fully integrated into Novo Nordisk R&D.

Click on the following links for more information.

OUR RESEARCH AREAS

Our discovery platform is focused on protein, peptide and antibodies.
We work in translational research and drug discovery and in collaboration with international scientific networks.

Our research focus is within the areas of:

  1. Novel insulin and incretin therapies e.g. glucose-sensitive insulin
  2. Novel glucose lowering mechanisms
  3. Stem cell based beta-cell-therapy and encapsulation
  4. Islet function and beta cell regeneration
  5. Immunotherapy in Type 1 Diabetes
  6. Diabetes Complications
  7. Obesity therapy
THE CURE OF DIABETES 

Novo Nordisk has different R&D programmes focusing on the Cure of Diabetes both within the Stem Cell area and Immunotherapy.

STEM CELL RESEARCH

IMMUNOTHERAPY

HISTORY OF HAGEDORN RESEARCH

Shortly after the discovery of insulin by Banting and Best in 1921, Professor August Krogh (1874-1949), Nobel Laureate in Physiology, and Dr. Hans Christian Hagedorn (1888-1971), a young diabetologist, obtained the rights from the discoverers in Toronto to produce insulin for the diabetics in Scandinavia

This formed the basis for the establishment of Nordisk Insulinlaboratorium in 1923. August Krogh, Hans Christian Hagedorn, and the pharmacist August Kongsted obtained Royal Charters for the non-profit foundation Nordisk Insulinlaboratorium in 1926.

That same year, the Nordisk Insulin Foundation was inaugurated, to support research within physiology and endocrinology, especially diabetes research in the Scandinavian countries. Meanwhile, in 1925, two brothers, Thorvald and Harald Pedersen, took up the competition and started Novo Terapeutisk Laboratorium.

Read More


THE HAGEDORN PRIZE

The Hagedorn Prize was established in connection with the 50th anniversary of the Danish Society for Internal Medicine to recognize the contribution to medical science made by Hans Christian Hagedorn (1888–1971).

For more information click here

HOW TO CONTACT US

If you have novel ideas/targets relevant for Novo Nordisk R&D research areas please contact our Sourcing unit for further interaction.

Click here to contact.

Following an established contact we have several different programmes to initiate and support collaborations with external partners including Ph.D. and Post. Doc. Programmes.

For more information on Novo Nordisk’s Ph.D and Post.Doc programmes click here.